Development of novel human chimeric antigen receptor-macrophages (CAR-M) as a potential therapeutic for amyloid clearance

Sep 6, 2022 Posters & Publications

AUTHORS: Manasi BalachandranJames. S. Foster, Joseph. W. Jackson, Tina Richey, Emily Martin, Stephen Kennel, Angela Williams, Sallie Macy, Craig Wooliver and Jonathan. S. Wall Amyloidosis and Cancer Theranostics ProgramDepartment of Medicine, University of Tennessee...

Results of the first-in-human PET/CT imaging study of the amyloid-reactive peptide 124I-AT-01 (124I-p5+14) for the detection of systemic amyloidosis

Sep 5, 2022 Posters & Publications

AUTHORS: Jonathan S. Wall1, Emily B. Martin1, Alan Stuckey1, Dustin Powell2, Tina Richey1, Angela Williams1, R. Eric Heidel3, Ronald Lands1, Stephen J. Kennel1 Departments of Medicine1, Radiology2 and Surgery3, University of Tennessee Graduate School of Medicine, TN,...

Pan-amyloid reactivity of radioiodinated peptide 124I-AT-01 in patients with systemic amyloidosis demonstrated by PET/CT imaging

Sep 5, 2022 Posters & Publications

AUTHORS: Emily B. Martin1, Alan Stuckey1, Dustin Powell2, Ronald Lands2, Spencer Guthrie3, Stephen J. Kennel1, and Jonathan S. Wall1 1 University of Tennessee Graduate School of Medicine, Knoxville, TN, USA 2 University of Tennessee Medical Center, Knoxville, TN, USA...

Attralus to Present New Data on Its Amyloidosis Portfolio at the 2022 International Symposium on Amyloidosis

Aug 22, 2022 Press Releases

PDF Version SAN FRANCISCO, Calif. – August 22, 2022 – Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to improve the lives of patients with systemic amyloidosis, today announced that new data across the Company’s...

Attralus Receives U.S. FDA Orphan Drug Designation for AT-01 (Iodine (I-124) Evuzamitide), an Investigational Diagnostic for the Management of Transthyretin Amyloidosis

Aug 8, 2022 Press Releases

PDF Version SAN FRANCISCO, Calif. – August 8, 2022 – Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to improve the lives of patients with systemic amyloidosis, announced today that the U.S. Food and Drug...